Twist Bioscience identifies competitive antibodies for SARS-CoV-2

Twist Bioscience identifies competitive antibodies for SARS-CoV-2

Source: 
Pharmaceutical Business Review
snippet: 


Twist Bioscience reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments. Twist’s unique monoclonal antibody candidates bind with high affinity to the receptor binding domain (RBD) on the S1 spike protein on the surface of SARS-CoV-2 viral molecules.